Systemic therapies in hepatocellular carcinoma: present and future.

  title={Systemic therapies in hepatocellular carcinoma: present and future.},
  author={G. Bertino and I. Di Carlo and A. Ardiri and Giuseppe Stefano Calvagno and S. Demma and G. Malaguarnera and N. Bertino and M. Malaguarnera and A. Toro},
  journal={Future oncology},
  volume={9 10},
  • G. Bertino, I. Di Carlo, +7 authors M. Malaguarnera
  • Published 2013
  • Medicine
  • Future oncology
  • Hepatocellular carcinoma (HCC) is now the third leading cause of cancer deathsworldwide and is generally presented at an advanced stage, limiting patients' quality of life. The conventional cytotoxic systemic therapy has proved to be ineffective in HCC, since its induction several decades ago. Today it is possible to use our knowledge of molecular hepatocarcinogenesis to provide a targeted therapy. Sorafenib has demonstrated large improvements in overall survival in HCC. This review describes… CONTINUE READING
    44 Citations
    Hepatocellular Carcinoma: Novel Molecular Targets in Carcinogenesis for Future Therapies
    • 73
    • PDF


    Systemic Therapies in Hepatocellular Carcinoma
    • 43
    Novel therapeutics in hepatocellular carcinoma: how can we make progress?
    • R. K. Kelley, A. Venook
    • Medicine
    • American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
    • 2013
    • 13
    Targeted agents and systemic therapy in hepatocellular carcinoma.
    • 19
    Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma
    • 208
    • PDF
    Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?
    • A. Zhu
    • Medicine
    • The oncologist
    • 2006
    • 240
    • PDF
    Molecular targeted therapies in hepatocellular carcinoma
    • 667
    Sorafenib for Treatment of Hepatocellular Carcinoma: A Systematic Review
    • 103
    HCC and angiogenesis: possible targets and future directions
    • 332